Piper Sandler Starts Coverage on Abbott Laboratories
Piper Sandler has kicked off its coverage on Abbott Laboratories (NYSE: ABT), giving it an 'overweight' rating along with a price target of $131 per share. This is a noteworthy endorsement for Abbott in today's ever-changing market.
Financial Strength and Growth Projections
A key reason behind Piper Sandler's recommendation is Abbott's strong financial standing and encouraging growth outlook. Analysts predict that Abbott’s revenue will rise from $41.68 billion in 2024 to about $44.84 billion by 2025, which equates to a growth rate of 7.6%. Additionally, earnings per share (EPS) are also expected to grow at a rapid pace, forecasted to jump from $4.65 in 2024 to $5.14 in 2025—an impressive increase of 10.5%.
Ongoing EPS Growth
Piper Sandler believes that Abbott’s EPS will continue to climb to $5.74 by 2026, showing a sustained growth rate of 11.7%. Given its current price of roughly $114.88, the stock is positioned as an attractive option, particularly with an estimated price-to-earnings ratio of 22.3x for 2025, according to the analysts.
Strength in the Medical Technology Division
Abbott's medical technology division, which accounts for around 44% of total revenue when excluding COVID-19 testing, is expected to be a crucial growth engine. The company anticipates this segment will enjoy double-digit growth through 2026, driven by innovative products like the FreeStyle Libre continuous glucose monitoring device and the MitraClip for structural heart therapy.
Innovation and Future Offerings
Piper Sandler has praised Abbott’s strong pipeline of innovation, filled with new products and technological advancements. Among the noteworthy upcoming products are the Lingo CGM aimed at the wellness market and the Volt pulsed field ablation (PFA) catheter expected to launch in 2026.
Assessing Risks and Market Standing
A crucial part of Piper Sandler’s optimistic view of Abbott hinges on its ability to maintain double-digit EPS growth, especially after the volatile revenue shifts caused by the pandemic. Market analysts believe Abbott is poised to rebound effectively from 2024, leading to solid EPS growth in 2025 and 2026, fueled by its performance across medical devices, diagnostics, pharmaceuticals, and nutrition.
Financial Resilience and Dividend History
Abbott’s financial strength is highlighted by its solid balance sheet, which includes $7.0 billion in cash as of mid-2024, alongside a favorable debt-to-EBITDA ratio of 0.64 when compared to industry counterparts. Furthermore, Abbott has consistently paid dividends for an impressive 402 consecutive quarters, making it an attractive option for investors, currently offering an annual dividend yield of 2.0%.
Challenges Ahead for Abbott Laboratories
Despite the bright outlook, Piper Sandler warns that challenges persist, particularly regarding ongoing litigation tied to Abbott’s Similac Special Care 24 formula. While this issue represents a small portion of total revenue (approximately $9 million in 2023), any potential legal liabilities could impact Abbott’s growth trajectory. Nevertheless, Piper suggests that much of this risk is already factored into the current market price, indicating that long-term growth potential remains promising.
Competitive Dynamics and Currency Challenges
Abbott faces competitive pressures, especially in the pulse field ablation space, where other firms like Boston Scientific and Medtronic are making significant advancements. Even though Abbott is in the process of developing its own PFA technology, it may lag behind competitors until 2026. Moreover, with 61% of its revenue coming from international markets, fluctuations in foreign currency exchange rates could pose additional challenges down the line.
Frequently Asked Questions
What rating did Piper Sandler give Abbott Laboratories?
Piper Sandler initiated coverage with an 'overweight' rating and a price target of $131.
How does Abbott's financial growth look for the upcoming years?
Analysts expect Abbott's revenues to grow to $44.84 billion in 2025, with a projected 7.6% increase.
What are the main products driving Abbott's revenue?
Key products include the FreeStyle Libre CGM device and MitraClip for structural heart therapy.
What is Abbott's track record on dividends?
Abbott has a history of paying dividends for 402 consecutive quarters, with a yield of 2.0% in 2023.
What competition does Abbott face in the medical technology sector?
Abbott faces competition from Boston Scientific and Medtronic, especially in the electrophysiology market.
